Colorectal cancer vaccines: The current scenario and future prospects

被引：31

作者：

Jia, Wenqing ^{[1
,2
]}

Zhang, Tao ^{[1
,2
]}

Huang, Haiyan ^{[1
,2
]}

Feng, Haoran ^{[1
,2
]}

Wang, Shaodong ^{[1
,2
]}

Guo, Zichao ^{[1
,2
]}

Luo, Zhiping ^{[1
,2
]}

Ji, Xiaopin ^{[1
,2
]}

Cheng, Xi ^{[1
,2
]}

Zhao, Ren ^{[1
,2
]}

机构：

[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Gen Surg, Sch Med, Shanghai, Peoples R China

[2] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Digest Surg, Sch Med, Shanghai, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

基金：

中国国家自然科学基金;

关键词：

colorectal cancer; vaccine; neoantigen; nanovaccines; immunotherapy; ACTIVE SPECIFIC IMMUNOTHERAPY; REDUCE TUMOR-GROWTH; I CLINICAL-TRIAL; PHASE-I; GM-CSF; NEUTRALIZING ANTIBODIES; ANTITUMOR EFFICACY; IMMUNE-RESPONSES; COLON-CANCER; ANTIGEN; 5T4;

D O I：

10.3389/fimmu.2022.942235

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Colorectal cancer (CRC) is one of the most common cancers worldwide. Current therapies such as surgery, chemotherapy, and radiotherapy encounter obstacles in preventing metastasis of CRC even when applied in combination. Immune checkpoint inhibitors depict limited effects due to the limited cases of CRC patients with high microsatellite instability (MSI-H). Cancer vaccines are designed to trigger the elevation of tumor-infiltrated lymphocytes, resulting in the intense response of the immune system to tumor antigens. This review briefly summarizes different categories of CRC vaccines, demonstrates the current outcomes of relevant clinical trials, and provides particular focus on recent advances on nanovaccines and neoantigen vaccines, representing the trend and emphasis of CRC vaccine development.

引用

页数：13

共 110 条

[41] Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283 [J].

Harris, JE ;

Ryan, L ;

Hoover, HC ;

Stuart, RK ;

Oken, MM ;

Benson, AB ;

Mansour, E ;

Haller, DG ;

Manola, J ;

Hanna, MG .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :148-157

[42] Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial [J].

Harrop, Richard ;

Connolly, Noel ;

Redchenko, Irina ;

Valle, Juan ;

Saunders, Mark ;

Ryan, Matthew G. ;

Myers, Kevin A. ;

Drury, Noel ;

Kingsman, Susan M. ;

Hawkins, Robert E. ;

Carroll, Miles W. .

CLINICAL CANCER RESEARCH, 2006, 12 (11) :3416-3424

[43] A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study) [J].

Hazama, Shoichi ;

Nakamura, Yusuke ;

Tanaka, Hiroaki ;

Hirakawa, Kosei ;

Tahara, Ko ;

Shimizu, Ryoichi ;

Ozasa, Hiroaki ;

Etoh, Ryuichi ;

Sugiura, Fumiaki ;

Okuno, Kiyotaka ;

Furuya, Takumi ;

Nishimura, Taku ;

Sakata, Koichiro ;

Yoshimatsu, Kazuhiko ;

Takenouchi, Hiroko ;

Tsunedomi, Ryouichi ;

Inoue, Yuka ;

Kanekiyo, Shinsuke ;

Shindo, Yoshitaro ;

Suzuki, Nobuaki ;

Yoshino, Shigefumi ;

Shinozaki, Hirokazu ;

Kamiya, Akira ;

Furukawa, Hiroyuki ;

Yamanaka, Takeharu ;

Fujita, Tomonobu ;

Kawakami, Yutaka ;

Oka, Masaaki .

JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12

[44] Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury [J].

Heery, Christopher R. ;

Singh, B. Harpreet ;

Rauckhorst, Myrna ;

Marte, Jennifer L. ;

Donahue, Renee N. ;

Grenga, Italia ;

Rodell, Timothy C. ;

Dahut, William ;

Arlen, Philip M. ;

Madan, Ravi A. ;

Schlom, Jeffrey ;

Gulley, James L. .

CANCER IMMUNOLOGY RESEARCH, 2015, 3 (11) :1248-1256

[45] ADJUVANT ACTIVE SPECIFIC IMMUNOTHERAPY FOR HUMAN COLORECTAL-CANCER - 6.5-YEAR MEDIAN FOLLOW-UP OF A PHASE-III PROSPECTIVELY RANDOMIZED TRIAL [J].

HOOVER, HC ;

BRANDHORST, JS ;

PETERS, LC ;

SURDYKE, MG ;

TAKESHITA, Y ;

MADARIAGA, J ;

MUENZ, LR ;

HANNA, MG .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :390-399

[46] Engineering a sustained release vaccine with a pathogen-mimicking manner for robust and durable immune responses [J].

Hou, Yingying ;

Liu, Rong ;

Hong, Xiaoyu ;

Zhang, Yunting ;

Bai, Shuting ;

Luo, Xianjin ;

Zhang, Yuandong ;

Gong, Tao ;

Zhang, Zhirong ;

Sun, Xun .

JOURNAL OF CONTROLLED RELEASE, 2021, 333 :162-175

[47] Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand? [J].

Hu, Li-Feng ;

Lan, Huan-Rong ;

Huang, Dong ;

Li, Xue-Min ;

Jin, Ke-Tao .

FRONTIERS IN ONCOLOGY, 2021, 11

[48] Vaccinations for Colorectal Cancer: Progress, Strategies, and Novel Adjuvants [J].

Jiang, Stephen ;

Good, David ;

Wei, Ming Q. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (14)

[49] Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer [J].

Kaufman, Howard L. ;

Lenz, Heinz-Josef ;

Marshall, John ;

Singh, Deepti ;

Garett, Chris ;

Cripps, Christine ;

Moore, Malcolm ;

von Mehren, Margaret ;

Dalfen, Richard ;

Heim, William J. ;

Conry, Robert M. ;

Urba, Walter J. ;

Benson, Al B., III ;

Yu, Maria ;

Caterini, Judy ;

Kim-Schulze, Seunghee ;

DeBenedette, Mark ;

Salha, Danielle ;

Vogel, Thorsten ;

Elias, Ileana ;

Berinstein, Neil L. .

CLINICAL CANCER RESEARCH, 2008, 14 (15) :4843-4849

[50] Cancer Immunoprevention: Current Status and Future Directions [J].

Keshavarz-Fathi, Mahsa ;

Rezaei, Nima .

ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2021, 69 (01)

← 1 2 3 4 5 6 7 8 9 10 →